Oncology & Immuno-Oncology
We aspire to turn cancer patients into survivors by delivering science-driven therapies that target the immune system AND the tumor.
- Long term vision- Merck KGaA Darmstadt, Germany has been around for more than 350 years
- Team members can develop drugs from concept through the clinic- which is rare in Pharma
- We are collaborative internally and competitive externally
Vision & strategy
- Focused Innovation
- Combination is Key
- Precision Medicine
We want to turn cancer patients into survivors by delivering science-driven therapies that target the immune system and the tumor.
What we do
Who are we TIP OIO
DDR DNA Damage Response ResearchRead more
Targeting genomic instability of cancer by selective inhibition of the DDR
Stress and Plasticity ResearchRead more
Focusing on oncogenic transcriptional regulators conferring tumor plasticity and resistance to current therapies as well as cancer associated proteotoxic and oxidative stress.
Oncogenic Signaling ResearchRead more
Centered around key oncogenic dependencies and apoptosis pathways complemented by the exploratory field of RNA processing biology (Currently running out of Darmstadt only)